Skip to main content
Top
Published in: Drug Safety 3/2002

01-03-2002 | Review Article

Cyclo-Oxygenase-2 Inhibitors and the Kidney

A Case for Caution

Authors: Gary Noroian, David Clive

Published in: Drug Safety | Issue 3/2002

Login to get access

Abstract

Cyclo-oxygenase (COX) is one of the key enzymes in the biosynthesis of prostaglandins. Two isoforms of this enzyme COX-1 and COX-2 are known to exist. Among other functions, prostaglandins play an important role in the protection of the gastric mucosa and maintenance of renal function in pathophysiological conditions which would otherwise threaten it. Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin synthesis, resulting in gastric mucosal injury and renal dysfunction in susceptible individuals. The recent introduction of selective COX-2 inhibitors, celecoxib and rofecoxib, appear to induce less gastrointestinal morbidity. Although conclusive data are still lacking, there is evidence to suggest that COX-2 antagonists may be capable of causing some of the same renal syndromes seen in association with the older, less selective NSAIDs.
Literature
1.
go back to reference Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686–92PubMedCrossRef Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686–92PubMedCrossRef
2.
go back to reference Wolfe MM, Licthenstein DR, Singh G. Medical progress: gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef Wolfe MM, Licthenstein DR, Singh G. Medical progress: gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef
3.
4.
go back to reference Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–72PubMedCrossRef Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–72PubMedCrossRef
5.
go back to reference Dunn MJ. Nonsteroidal antiinflammatory drugs and renal function. Ann Rev Med 1984; 34: 411–28CrossRef Dunn MJ. Nonsteroidal antiinflammatory drugs and renal function. Ann Rev Med 1984; 34: 411–28CrossRef
6.
go back to reference Palmer BF. Renal complications associated with use of nonsteroidal antiinflammatory drugs. J Investig Med 1995; 43: 516–33PubMed Palmer BF. Renal complications associated with use of nonsteroidal antiinflammatory drugs. J Investig Med 1995; 43: 516–33PubMed
7.
go back to reference Zimran A. Kramer M. Incidence of hyperkalemia induced by indomethacin in a hospital population. BMJ 1985; 291: 107–8PubMedCrossRef Zimran A. Kramer M. Incidence of hyperkalemia induced by indomethacin in a hospital population. BMJ 1985; 291: 107–8PubMedCrossRef
8.
go back to reference Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetominophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675–9PubMedCrossRef Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetominophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675–9PubMedCrossRef
9.
go back to reference Stillman MT, Napier J, Blackshear JL. adverse effects of nonsteroidal anti-inflammatory drugs on the kidney. Med Clin North Am 1984; 65: 371–85 Stillman MT, Napier J, Blackshear JL. adverse effects of nonsteroidal anti-inflammatory drugs on the kidney. Med Clin North Am 1984; 65: 371–85
10.
go back to reference Golden BD, Abramson SB. Selective COX-2 inhibitors for arthritis: from bench to bedside. Rhema 21st, Cutting Edge Reports 1999: 1–10 Golden BD, Abramson SB. Selective COX-2 inhibitors for arthritis: from bench to bedside. Rhema 21st, Cutting Edge Reports 1999: 1–10
11.
go back to reference Crofford LF, Lipsky PE, Brooks P, et al. basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 4–13PubMedCrossRef Crofford LF, Lipsky PE, Brooks P, et al. basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 4–13PubMedCrossRef
12.
go back to reference Ichitani Y, Holmberg K, Maunsbach AB, et al. Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies. Cell Tissue Res 2001; 303: 235–52PubMedCrossRef Ichitani Y, Holmberg K, Maunsbach AB, et al. Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies. Cell Tissue Res 2001; 303: 235–52PubMedCrossRef
13.
go back to reference Schaefers HJ, Goppelt-Struebe M. Interference of corticosteroids with prostaglandin E2 synthesis at the level of cyclooxygenase-2 mRNA expression in kidney cells. Biochem Pharmacol 1996; 52: 1415–21PubMedCrossRef Schaefers HJ, Goppelt-Struebe M. Interference of corticosteroids with prostaglandin E2 synthesis at the level of cyclooxygenase-2 mRNA expression in kidney cells. Biochem Pharmacol 1996; 52: 1415–21PubMedCrossRef
14.
go back to reference Vio CP, An SJ, Cespedes C, et al. Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol 2001; 12: 649–58PubMed Vio CP, An SJ, Cespedes C, et al. Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol 2001; 12: 649–58PubMed
15.
go back to reference Stichtentoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Design 2000; 6: 1737–53CrossRef Stichtentoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Design 2000; 6: 1737–53CrossRef
16.
go back to reference Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000; 11: 2387–94PubMed Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000; 11: 2387–94PubMed
17.
go back to reference Norwood VF, Morham SG, Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 2000; 58: 2291–300PubMedCrossRef Norwood VF, Morham SG, Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 2000; 58: 2291–300PubMedCrossRef
18.
go back to reference Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol Renal Physiol 1998; 274: F481–9 Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol Renal Physiol 1998; 274: F481–9
19.
go back to reference Harris RC, McKanna JA, Akai Y, et al. Cyclo-oxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–10PubMedCrossRef Harris RC, McKanna JA, Akai Y, et al. Cyclo-oxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–10PubMedCrossRef
20.
go back to reference Lorenz JN, Greenberg SG. The macula densa of rat kidney and increases with salt restriction. Semin Nephrol 1993; 13: 531–40PubMed Lorenz JN, Greenberg SG. The macula densa of rat kidney and increases with salt restriction. Semin Nephrol 1993; 13: 531–40PubMed
21.
go back to reference Harding P, Sigmon DH, Alfie ME, et al. Cyclo-oxygenase-2 mediates increased renal renin content induced by low sodium diet. Hypertension 1997; 29: 297–302PubMedCrossRef Harding P, Sigmon DH, Alfie ME, et al. Cyclo-oxygenase-2 mediates increased renal renin content induced by low sodium diet. Hypertension 1997; 29: 297–302PubMedCrossRef
22.
go back to reference Harding P, Carretero OA, Beierwlates WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal hemodynamics. J Hypertens 2000; 18: 1107–13PubMedCrossRef Harding P, Carretero OA, Beierwlates WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal hemodynamics. J Hypertens 2000; 18: 1107–13PubMedCrossRef
23.
go back to reference Cheng HF, Wang JL, Zhang MZ, et al. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001; 280: F449–56PubMed Cheng HF, Wang JL, Zhang MZ, et al. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001; 280: F449–56PubMed
24.
go back to reference Wang JL, Cheng HF, Harris RC. Cyclo-oxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999, 34: 96–101PubMedCrossRef Wang JL, Cheng HF, Harris RC. Cyclo-oxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999, 34: 96–101PubMedCrossRef
25.
go back to reference Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000; 36: 276–81PubMedCrossRef Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000; 36: 276–81PubMedCrossRef
26.
go back to reference Abassi Z, Brodsky S, Gealekman O, et al. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 2001; 280: F43–F53PubMed Abassi Z, Brodsky S, Gealekman O, et al. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 2001; 280: F43–F53PubMed
27.
go back to reference Tomasoni S, Noris M, Zappella S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998, 9; 1202–12PubMed Tomasoni S, Noris M, Zappella S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998, 9; 1202–12PubMed
28.
go back to reference Bosch-Marce M, Claria J, Titos E, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116: 1167–75PubMedCrossRef Bosch-Marce M, Claria J, Titos E, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116: 1167–75PubMedCrossRef
29.
go back to reference Gross JM, Dwyer JE, Knox FG. Natiuretic respone to increased pressure is preserved with COX-2 inhibitors. Hypertension 1999; 34: 1163–7PubMedCrossRef Gross JM, Dwyer JE, Knox FG. Natiuretic respone to increased pressure is preserved with COX-2 inhibitors. Hypertension 1999; 34: 1163–7PubMedCrossRef
30.
go back to reference Blume C, Heise G, Muhlfeld A, et al. Effect of flosulide, a selective cyclooxygenase-2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56(5): 1770–8PubMedCrossRef Blume C, Heise G, Muhlfeld A, et al. Effect of flosulide, a selective cyclooxygenase-2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56(5): 1770–8PubMedCrossRef
31.
go back to reference Wang JL, Cheng HF, Shappell S, et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334–42PubMedCrossRef Wang JL, Cheng HF, Shappell S, et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334–42PubMedCrossRef
32.
go back to reference Wang JL, Cheng HF, Zhang MZ, et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275: F613–F622PubMed Wang JL, Cheng HF, Zhang MZ, et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275: F613–F622PubMed
33.
go back to reference Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clinical Invest 2001; 107: 889–98CrossRef Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clinical Invest 2001; 107: 889–98CrossRef
34.
go back to reference Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1–9PubMed Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1–9PubMed
35.
go back to reference Rossat J, Maillare M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76–84PubMedCrossRef Rossat J, Maillare M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76–84PubMedCrossRef
36.
go back to reference Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465–70PubMedCrossRef Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465–70PubMedCrossRef
37.
go back to reference Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subject with rhematic disease and mild renal impairment. Br J Rheumatol 1996; 35Suppl. 1: 56–60PubMedCrossRef Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subject with rhematic disease and mild renal impairment. Br J Rheumatol 1996; 35Suppl. 1: 56–60PubMedCrossRef
38.
go back to reference Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–41PubMed Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–41PubMed
39.
go back to reference Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthrits and rheumatoid arthritis. JAMA 2000; 284: 1247–55PubMedCrossRef Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthrits and rheumatoid arthritis. JAMA 2000; 284: 1247–55PubMedCrossRef
40.
go back to reference Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of clelcoxib, a novel cyclooxygenase-2 inhibitor. Am J Therapeut 2000; 7: 159–72CrossRef Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of clelcoxib, a novel cyclooxygenase-2 inhibitor. Am J Therapeut 2000; 7: 159–72CrossRef
41.
go back to reference Perrazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 5: 937–40CrossRef Perrazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 5: 937–40CrossRef
Metadata
Title
Cyclo-Oxygenase-2 Inhibitors and the Kidney
A Case for Caution
Authors
Gary Noroian
David Clive
Publication date
01-03-2002
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2002
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225030-00003

Other articles of this Issue 3/2002

Drug Safety 3/2002 Go to the issue